While we wait for several of our April picks to blossom and bloom (ah yes, the metaphors of Spring), a new ticker has hit our radars that just might be in the process of sprouting as we speak: GGII

GGII is currently trading at 6 cents. Keep GGII on your watchlist. We love this one for April and most likely through May 2010. Remember always do your own due diligence and never invest money in any OTC stock that you are not willing to lose. ALL OTC stocks are risky and highly speculative!

Thanks for the great feedback lately! Keep it coming.

Your Humble Servants,

The OTC Times

ENTB, Entest Biomedical Inc., has been and currently is a strong stock. We have been following this stock for a while now and consistently see progression in the right direction. What ENTB is doing is focusing in on one specific area, a COPD cure, and earning revenue on things they find along the way. An example of this would be the newly discovered stem cell line they have claimed.

With the finding of the new stem cell line, ENTB can partner with existing companies and sell them usage rights. This means that ENTB can help fund their COPD endeavors and maintain a self-sufficient status. Translating this into the investor’s hands is a better PPS and more profit lines.

During our steady gain there have been profit takers along the way, which is to be expected; however, it has not affected the stock price negatively. The company principals are just as sound as the stock, as well, which makes for a win-win situation for shareholders.

Those investors in ENTB know what kind of gem ENTB is and it has not widely been exposed. The growth we have seen from this stock is nothing short of productive and should continue its upward path before it shoots straight up with news of a breakthrough in the COPD treatment.

It is not every day that investors find a stock that they can set aside and let mature. ENTB is one of those stocks and the potential to hit the all-time high is clearly within grasp. For those who would like to do due diligence on ENTB, visit their blog site located at http://www.entestbioblog.com and click on “live” to see webcasts that the company has previously done live. This will give you a good insight on the steps the company is taking to achieve their goals. They have recently started adding guests to their live webcasts to help clarify points in the process of creating the COPD treatment happen.

Reviewing past press releases and searching online will provide plenty of necessary information to understand why Entest Biomedical, Inc. is a solid investment. With COPD being the fourth leading cause of death in the United States, there is a huge potential for large sums of money to be made by the company and shareholders. A little patience with ENTB stands to go a very long way indeed. We would love to be in on the ground floor of a company that ultimately finds the cure for the 4th leading cause of death in the U.S. The thought of what an achievement such as that would have on the share price is mind-boggling!

We will publish our new picks for April tomorrow after the bell, but we have a pretty good idea where we’re headed and wanted to give our readers a heads up on the stocks we think represent good investment and/or trading opportunities for April 2010.

HBRM looks to us to be a relatively undiscovered company that specializes in botanical therapeutics and has what appears to be a product that might cure acne. The stock is currently trading around .02 per share.

ENTB alerted by us at around 1.05 and continues to impress on an almost daily basis. ENTB is currently trading around 2.05 per share.

BMSN the parent/sister company of ENTB. As ENTB gets noticed by the big rollers we think BMSN will as well. It is currently trading around .125 per share.

AMSZ we have now heard from several different investors that have a proven track record with us that believe that AMSZ could have a great big month in April. It is currently trading around .011 per share.

GSRE is our sub-penny pick for the month of April. It is currently trading around .002 per share.

There are a handful of others we continue to monitor that may make the list but right now these represent our top five. Any feedback on these stocks and others that you like is always welcome!

CVRG has been one of the “Stocks We Love” since .02. In looking at this stock over the last several sessions we here at The OTC Times believe that the stock is getting serious about starting a new uptrend. Further confirming our thoughts about the uptrend is the fantastic after hours news the company released on Friday. Here are a couple of snippets from the full news release.

The Company acquired 100% of the Eagle Nest Mining Property, which is comprised of 25 lode type mining claims totaling approximately 256 hectares (633 acres) in the Buckskin Mountains, La Paz County, Arizona, a well known and historical mining district.

"The veins are consistent with the epithermal, detachment fault type of lode gold deposit commonly found within Arizona." Mr. Hawkins states. "Detailed prospecting of the remaining property area, staking additional claims and undertaking a diamond drill program is recommended to determine the extent of the economic potential."

"Laboratory analysis confirmed that the main and south zones at the Eagle Nest Mining Property are hosts to gold, silver and copper mineralization." Mr. Hawkins concludes, "Values are high enough to be of economic potential."

As always, investors are encouraged to perform your own due diligence. A few places we like to look to find worthwhile due diligence include:

• Company Website — http://www.convergeglobalinc.com/
• Recent Press Releases — http://finance.yahoo.com/q/h?s=CVRG.PK
• Public Filings/Information — http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=cvrg#getCompanyInfo 
• Public message boards (performing a Google search should yield several results)

In looking at the CVRG chart for the last 2 months, we notice that the .033 level has been tested at least 3 times. We think that if CVRG manages to break this resistance this week we should see a decent move higher. We think investors looking for near-term gains should give CVRG a close look right now!

The company Entest Biomedical (ENTB) continues to hone in on their goals while securing potential funding opportunities on the way. This is possibly one of the most alluring positions of this stock. Not only is ENTB endlessly trying to find a solid treatment/cure for COPD but also making headway in other areas that stand to increase the value of the company exponentially.

The CEO and Chairman of ENTB states: "Since some of these technologies may be useful in augmentation of stem cell therapy for other indications, we are always looking for partnerships for development in our non-core areas." This shows that they are continuing to focus in on their ultimate goal of an FDA-approved treatment for COPD but leaving the door open to pursue partnerships and other sources of funds along the way. To investors, this stock is panning out to be a perfect match of research with real progress.

The patent Entest Biomedical, Inc. is filing for is for the use of stem cell attracting chemokines in treating COPD in addition to other medical conditions that can benefit from stem cell homing. Essentially, it is increasing the number of stem cells in the tissues where they are needed throughout the body to increase repair.

Stem cell trials show that they are safe and increase desired results in liver and heart failure as well as peripheral artery disease; however, more tests need to be conducted to improve the actual patient’s outcomes.

What ENTB is doing is completely different than current cell homing which involves making stem cells leave areas such as bone marrow. ENTB is using chemokines, the attracting molecule, to bring in the stem cells. Overall, the process is very safe and could potentially produce a much more effective outcome.

We have said it before and our opinions have not changed; ENTB is on a mission to bring the best out of medicine and explore areas that have not been explored or revisit past methods and make them more efficient or better yet, a solution to a problem.

This new patent application is just one of the many announcements we expect to hear from Entest Biomedical, Inc. Their mission is clear, they uphold stockholder value and they look beyond what is in front of them and into the future. This is the type of company that we want paving the ways to new discoveries in medicine and we will be there every step of the way.

Today, the CEO Dr. David Koos and ENTB’s Lead Inventor discussed the recent patent more in-depth. You will not want to miss the video and can view it online right now here: http://www.entestbioblog.com/entb-live-webcast-on-march-24-2010/

EXPU has been on our “Stocks We Love” list since .046. Since the time we put EXPU on our list back in late 2009 until now the stock has traveled as high as .21 before pulling ALL THE WAY BACK! In fact, EXPU has recently hit as low as .04 and we here at The OTC Times believe that the stock is drastically oversold. EXPU presents a real opportunity for the bargain-minded investor.

If oodles of new shares had been added to the float, we’d be freaked out about adding more. But the share structure remains firm at 46.5M o/s and 25.5M in the float!

If genuine progress from the company had ceased, we’d be freaked out about adding more. But the company released news today that shows that they are on the right track! LOOK HERE!

If the CEO went into hiding, we’d be freaked out about adding more as well! But the CEO is hosting a live conference call tomorrow! This is most certainly not the behavior of a typical pinksheet CEO.

We are convinced that NOW is the time to pay very close attention to EXPU.

We still believe that EXPU will head back up into the double digits before long. Look at the chart below. Do some due diligence. And then consider whether we’re right on the money (as usual) or we’re off our rocker when we say that this stock represents an excellent opportunity to buy low and sell high in the NEAR FUTURE!

Good evening readers! In a tough OTC market a couple of our favorite picks stood out like shining jewels today as investors gobbled up shares.

We were thoroughly impressed today with the second live videoconference with Dr. David Koos, CEO of Entest Biomedical (ENTB). The stock responded well on the day as well, closing green on strong volume.

We believe there is much more to come with this fully reporting OTCBB. Based on what investors close to OtcTimes.com have told us, we think there is a strong probability that some institutional buying could occur with ENTB. We just love the chart and could easily see this continuing to move higher. It has proven an ability to bust through any and all resistance points so far!

Another stock that has been on our “love list” this month is VYGO. One look at the chart tells us that people are accumulating VYGO. VYGO has definitely caught our lately and we are looking at adding to our position tomorrow. We think that VYGO has the potential to be a several-hundred-percent gainer. As you look at the chart notice how it fell from higher price points on moderately low volume. Then look at how over the past several sessions the volume has increased along with the share price. We feel like this one will not only retest previous highs, but utterly blow past them with liquid authority!